Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • Pulse Biosciences' Cash from Financing Activities fell 9682.39% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year increase of 355.74%. This contributed to the annual value of $110.1 million for FY2024, which is 57208.32% up from last year.
  • Per Pulse Biosciences' latest filing, its Cash from Financing Activities stood at $2.0 million for Q3 2025, which was down 9682.39% from $14.8 million recorded in Q1 2025.
  • In the past 5 years, Pulse Biosciences' Cash from Financing Activities ranged from a high of $65.1 million in Q3 2022 and a low of -$549000.0 during Q4 2021
  • For the 5-year period, Pulse Biosciences' Cash from Financing Activities averaged around $15.9 million, with its median value being $3.1 million (2021).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 1927803.03% in 2021, then crashed by 56461.54% in 2023.
  • Pulse Biosciences' Cash from Financing Activities (Quarter) stood at -$549000.0 in 2021, then skyrocketed by 96.9% to -$17000.0 in 2022, then surged by 4829.41% to $804000.0 in 2023, then soared by 5895.27% to $48.2 million in 2024, then tumbled by 95.92% to $2.0 million in 2025.
  • Its Cash from Financing Activities was $2.0 million in Q3 2025, compared to $14.8 million in Q1 2025 and $48.2 million in Q4 2024.